Foghorn and Lilly halt FHD-909 development to focus pipeline
Foghorn Therapeutics terminated its collaboration with Eli Lilly to not advance FHD-909, citing insufficient efficacy. The company is reducing its workforce by 40% and reallocating resources to its proprietary pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed